All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000050-23 | Prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic major depre... | 2006-07-17 | due-trials |
| Reported results | 2004-000073-64 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MR... | 2006-01-06 | due-trials |
| Reported results | 2004-000074-31 | A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients | 2005-05-09 | due-trials |
| Reported results | 2004-000120-32 | "Inhibición precoz de la glucoproteina IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: ensayo aleatorizado y controlado con placebo para evaluar los efectos clínicos beneficioso... | 2009-08-28 | due-trials |
| Reported results | 2004-000311-26 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz... | 2005-11-10 | due-trials |
| Reported results | 2004-000312-93 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin... | 2007-03-09 | due-trials |
| Reported results | 2004-000313-19 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | 2007-03-09 | due-trials |
| Reported results | 2004-000390-59 | Safety and Efficacy of SCH-417690 in HIV-infected Treatment-Naive Subjects | 2005-12-01 | due-trials |
| Reported results | 2004-000424-32 | A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults with Invasive Candida Infections (Excluding Patients with... | 2006-02-10 | due-trials |
| Reported results | 2004-000469-36 | A multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomo... | 2009-01-15 | due-trials |
| Reported results | 2004-000472-14 | A multicenter, randomized, parallel-group, double- blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasom... | 2006-01-15 | due-trials |
| Reported results | 2004-000487-27 | A Double-Blind, Parallel-Group, 4-week Trial to Assess the Efficacy and Safety of Etoricoxib 60mg and Diclofenac 150mg in Patients with Chronic Low Back Pain | 2005-03-15 | due-trials |
| Reported results | 2004-000488-83 | A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response | 2008-05-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-000558-22 | Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis C | 2013-01-10 | bad-data |
| Reported results | 2004-000612-54 | A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoa... | 2004-11-04 | due-trials |
| Reported results | 2004-000614-39 | A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma. | 2007-05-10 | due-trials |
| Reported results | 2004-000820-34 | Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients | 2008-03-31 | due-trials |
| Reported results | 2004-000867-92 | A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | 2006-05-10 | due-trials |
| Reported results | 2004-000959-42 | Avoin, randomis., rinnakkaisryhmillä tehtävä monikeskustutk., jossa tutk. tehoa ja turvallisuutta vertailtaessa lääkityksen vaihtamista rosuvastatiiniin 10 mg päivässä verrattuna atorvastatiiniin 10... | 2005-06-23 | due-trials |
| Reported results Terminated | 2004-001177-25 | Cardiac safety profile of Caelyx therapy in anthracyclin pretreated metastatic breast cancer patients. | 2006-08-28 | due-trials |
| Reported results | 2004-001220-20 | Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys | 2008-06-23 | due-trials |
| Reported results | 2004-001376-39 | Long-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control. | 2006-10-15 | due-trials |
| Reported results | 2004-001580-22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitoste... | 2005-10-01 | due-trials |
| Reported results | 2004-001750-81 | A randomized, double-blind, placebo-controlled study to evaluate the persistence of the effect of oral monthly ibandronate on bone resorption in postmenopausal women with osteoporosis | 2005-06-13 | due-trials |
| Reported results | 2004-001883-39 | Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have ... | 2005-01-14 | due-trials |
| Reported results | 2004-001907-36 | A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | 2006-07-31 | due-trials |
| Reported results | 2004-002156-34 | Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episode,... | 2006-06-09 | due-trials |
| Reported results | 2004-002159-16 | A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi... | 2007-06-08 | due-trials |
| Reported results | 2004-002160-22 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Contr... | 2006-07-27 | due-trials |
| Reported results | 2004-002236-26 | A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Co-administration Of Ezetimibe 10 Mg With Ongoing Treatment with S... | 2007-02-16 | due-trials |
| Reported results | 2004-002345-12 | An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Co... | 2009-02-22 | due-trials |
| Reported results | 2004-002560-17 | A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophre... | 2007-08-02 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-002627-40 | Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia | 2007-06-28 | bad-data |
| Reported results | 2004-002930-21 | Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Densit... | 2009-11-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-002945-10 | A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci... | 2017-08-22 | bad-data |
| Reported results | 2004-002988-24 | A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in e... | 2007-05-17 | due-trials |
| Reported results | 2004-003000-37 | A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients ... | 2005-10-28 | due-trials |
| Reported results | 2004-003807-19 | A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia | 2005-09-29 | due-trials |
| Reported results | 2004-003819-23 | A multi-center, randomized, parallel dose-finding, safety-assessor blinded trial to explore the efficacy, safety and pharmacokinetics of four doses of Org 25969 and placebo in pediatric and adult subj... | 2006-06-02 | due-trials |
| Reported results Terminated | 2004-003927-11 | A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of an... | 2007-03-22 | due-trials |
| Reported results Terminated | 2004-003989-15 | Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study. | 2008-10-24 | due-trials |
| Reported results Terminated | 2004-004113-42 | SCH 486757 vs Codeine and Placebo in Subjects with Persistent Postviral Cough | 2007-04-02 | due-trials |
| Reported results | 2004-004302-24 | A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety and Tolerability of L-000883191 in Rheumatoid Arthritis | 2005-11-21 | due-trials |
| Reported results | 2004-004685-32 | A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusi... | 2008-08-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-004709-53 | A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patients A... | 2008-11-14 | bad-data |
| Reported results | 2004-004771-11 | A phase III, randomized, double-blind, active-controlled, non-inferiority clinical trial to investigate the efficacy and safety of a single injection of Org 36286 (corifollitropin alfa) to induce mult... | 2008-11-29 | due-trials |
| Reported results | 2004-004772-36 | Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38819 for Org 36286 (corifollitropin alfa) | 2009-04-16 | due-trials |
| Reported results | 2004-004773-28 | Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819 | 2009-05-07 | due-trials |
| Reported results | 2004-004966-34 | A Phase III, open-label trial to assess the non-immunogenicity and safety of Org 36286 in patients undergoing repeated controlled ovarian stimulation cycles using either a multiple dose GnRH antagonis... | 2009-04-08 | due-trials |
| Reported results | 2004-004967-30 | Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38825 for Org 36286 (corifollitropin alfa) | 2010-01-21 | due-trials |
| Reported results | 2004-005023-18 | Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade | 2006-05-10 | due-trials |
| Reported results | 2004-005037-19 | Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Back... | 2009-07-17 | due-trials |
| Reported results | 2005-000085-39 | An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis | 2008-06-19 | due-trials |
| Reported results | 2005-000093-50 | A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C... | 2007-01-25 | due-trials |
| Reported results | 2005-000407-34 | A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic... | 2008-02-29 | due-trials |
| Reported results | 2005-000733-37 | A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypop... | 2006-04-01 | due-trials |
| Reported results | 2005-000949-11 | A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico... | 2011-11-21 | due-trials |
| Reported results | 2005-001057-21 | VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in experienced subjects VICTOR-E1 . | 2011-03-17 | due-trials |
| Reported results Terminated | 2005-001058-26 | VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in Experienced subjects VICTOR E2 . | 2006-10-04 | due-trials |
| Reported results | 2005-001059-39 | A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac... | 2014-09-18 | due-trials |
| Reported results | 2005-001133-15 | A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearanc... | 2006-03-06 | due-trials |
| Reported results | 2005-001134-32 | A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy and safety of 5 doses of Org 25969 administered at 1-2 PTC after rocuronium or vecuronium in... | 2006-04-11 | due-trials |
| Reported results | 2005-001135-30 | A multi-center, randomized, parallel group, comparative, active controlled, safety-assessor blinded, phase IIIa, pivotal trial, in adult subjects comparing Org 25969 with neostigmine as reversal agent... | 2006-03-06 | due-trials |
| Reported results | 2005-001264-31 | PEG-Intron/Rebetol vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 Dose Finding Phase 2 Study | 2007-06-20 | due-trials |
| Reported results | 2005-001472-12 | A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalproe... | 2007-12-11 | due-trials |
| Reported results | 2005-001511-22 | A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Wom... | 2016-01-20 | due-trials |
| Reported results | 2005-001792-35 | Comparison of rocuronium and Org 25969 with cis-atracurium and neostigmine when neuromuscular block is reversed at reappearance of T2 | 2006-05-25 | due-trials |
| Reported results Terminated | 2005-001843-49 | Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Substudy of P03802 | 2005-11-15 | due-trials |
| Reported results | 2005-001889-13 | Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. | 2008-10-29 | due-trials |
| Reported results | 2005-001890-83 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor AntagoN... | 2006-09-21 | due-trials |
| Reported results | 2005-002000-42 | A multi-center, randomized, parallel-group, placebo-controlled, safety-assessor blinded trial, evaluating the safety and efficacy of Org 25969 in cardiac patients | 2006-08-01 | due-trials |
| Reported results | 2005-002113-21 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter 16 Week Study to Assess the Effect of Vitamin D3 8400 IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Over 70 Years ... | 2006-07-18 | due-trials |
| Reported results | 2005-002118-39 | RECAP-DM (Real-life Effectiveness and Care Patterns of Diabetes Management) | 2007-02-28 | due-trials |
| Reported results | 2005-002169-35 | A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 | 2008-01-16 | due-trials |
| Reported results | 2005-002189-12 | A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate (MTX) alone for the treatment of MTX naïve subjects with Active Psoriatic Arthritis | 2008-03-20 | due-trials |
| Reported results | 2005-002364-29 | A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients | 2008-10-02 | due-trials |
| Reported results | 2005-002454-21 | A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of L-000899055 in Obese Patients | 2009-02-10 | due-trials |
| Reported results Terminated | 2005-002509-22 | A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture | 2007-08-22 | due-trials |
| Reported results | 2005-002650-22 | A Mulitcenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma | 2008-04-16 | due-trials |
| Reported results | 2005-002926-67 | An open-label, randomized, phase IIIB, multicenter trial to evaluate the pharmacodynamic parameters of intubation bolus, and bolus and infusion maintenance doses of Zemuron® in pediatric and adolescen... | 2007-07-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-002928-34 | A randomized, assessor-blind, dose-ranging, phase IIIB, multicenter trial comparing the intubating conditions and time course of block of three different intubating doses (0.45 mg/kg, 0.6 mg/kg, and 1... | 2007-07-26 | bad-data |
| Reported results | 2005-003035-52 | A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (Ina... | 2006-03-08 | due-trials |
| Reported results | 2005-003508-12 | Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children | 2007-06-14 | due-trials |
| Reported results | 2005-003717-33 | Open-Label, limited access protocol of Posaconazole in invasive fungal infections. | 2007-03-08 | due-trials |
| Reported results Terminated | 2005-003749-15 | Investigation of the effectiveness of oral lorazepam in managing preoperative dental anxiety in phobic dental patients-A pilot study | 2006-12-18 | due-trials |
| Reported results | 2005-003869-17 | A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Melli... | 2007-02-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-003876-39 | A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients W... | bad-data | |
| Reported results Terminated | 2005-004287-23 | Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD | 2008-10-29 | due-trials |
| Reported results Terminated | 2005-004289-18 | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 4... | 2011-04-07 | due-trials |
| Reported results | 2005-004309-27 | Cross-Over Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber | 2006-02-01 | due-trials |
| Reported results | 2005-004464-24 | A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Al... | 2006-12-12 | due-trials |
| Reported results | 2005-004465-41 | A multi-center, open-label trial evaluating the Efficacy, Safety and the Impact on Quality of Life of Infliximab Therapy in patients with moderate to severe psoriasis not responding and/or intolerant ... | 2009-05-25 | due-trials |
| Reported results | 2005-004499-19 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder | 2006-10-18 | due-trials |
| Reported results | 2005-004504-36 | A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. | 2008-04-28 | due-trials |
| Reported results | 2005-004712-73 | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomitin... | 2008-03-27 | due-trials |
| Reported results | 2005-004848-31 | A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Administration Of Ezetimibe/Simvastatin tablet 10/20 Mg Versus Dou... | 2007-03-27 | due-trials |
| Reported results | 2005-005050-47 | A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of Org 25969 in subjects with normal or impaired renal function. | 2006-04-13 | due-trials |
| Reported results | 2005-005093-70 | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholes... | 2006-12-08 | due-trials |
| Reported results | 2005-005094-30 | A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B (dosed as coadministered MK 0524A and simvastatin Tablets) in Patients ... | 2007-01-18 | due-trials |
| Reported results | 2005-005127-34 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimi... | 2011-05-18 | due-trials |
| Reported results | 2005-005146-39 | A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subje... | 2008-11-03 | due-trials |
| Reported results | 2005-005304-16 | A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic COC containing 2.5 mg nomegestrol acetate NOMAC ... | 2008-04-10 | due-trials |
| Reported results | 2005-005367-28 | A Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-type Psoriasis | 2009-01-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-005449-20 | Double blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet th... | 2007-11-21 | bad-data |
| Trial is partly outside EEC, and reported results | 2005-005450-45 | A double blind, randomized, placebo-controlled, parallel group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet ... | 2008-04-03 | bad-data |
| Reported results Terminated | 2005-005606-23 | A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder | 2007-09-24 | due-trials |
| Reported results | 2005-005910-20 | A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously treated With... | 2008-01-30 | due-trials |
| Exempt, with results | 2005-005939-10 | A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine | 2007-05-10 | not-yet-due |
| Reported results | 2005-005984-27 | A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma... | 2010-04-16 | due-trials |
| Reported results | 2005-006048-42 | A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects With ... | 2008-03-06 | due-trials |
| Reported results Terminated | 2005-006201-12 | A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder | 2007-09-24 | due-trials |
| Reported results | 2006-000481-37 | A randomized, open-label clinical trial to identify predictive factors for controlled ovarian stimulation using a fixed daily dose of 200 IU of recombinant FSH in a GnRH antagonist regimen with or wit... | 2008-07-24 | due-trials |
| Reported results | 2006-000606-23 | Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase Estudio po... | 2010-11-15 | due-trials |
| Reported results | 2006-000676-33 | A randomized, open-label, comparative, multi-center trial to evaluate the effects on hemostasis, lipids and carbohydrate metabolism, and on adrenal and thyroid function of a monophasic COC containing ... | 2008-01-21 | due-trials |
| Reported results | 2006-000764-85 | A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age | 2008-02-21 | due-trials |
| Reported results | 2006-001335-22 | A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100mg Once Daily in Patients with Type 2 Diabetes With I... | 2007-03-16 | due-trials |
| Reported results | 2006-001392-37 | A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metfo... | 2007-08-15 | due-trials |
| Reported results | 2006-001449-33 | A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily). | 2009-04-04 | due-trials |
| Reported results | 2006-001452-12 | An open-label, non-controlled multicentre trial to evaluate the insertion characteristics of the radiopaque etonogestrel implant using a next generation applicator | 2010-10-20 | due-trials |
| Reported results | 2006-001546-14 | A randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estra... | 2008-01-29 | due-trials |
| Reported results | 2006-001577-13 | A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with Pe... | 2008-08-31 | due-trials |
| Reported results | 2006-001578-25 | A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with Pe... | 2008-09-23 | due-trials |
| Reported results | 2006-001579-40 | Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab | 2008-11-26 | due-trials |
| Reported results | 2006-001637-18 | A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure... | 2009-07-30 | due-trials |
| Reported results | 2006-001638-42 | Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 M... | 2007-10-24 | due-trials |
| Reported results | 2006-001639-23 | A Study to Assess the Anamnestic Immune Response 4 to 6 Years After a Primary Vaccination Series With HBVAXPRO™ Estudio para evaluar la respuesta inmune anamnésica 4 a 6 años después de una pauta de v... | 2008-06-23 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-001761-42 | A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Pre... | bad-data | |
| Reported results Terminated | 2006-001913-13 | A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery... | 2008-05-20 | due-trials |
| Reported results Terminated | 2006-002090-47 | An Efficacy and Tolerability Study of MK-0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | 2007-10-24 | due-trials |
| Reported results | 2006-002164-26 | Study of the Efficacy and Safety of SCH619734 in Subjects with Chronic Idiopathic Cough | 2007-10-22 | due-trials |
| Reported results | 2006-002165-39 | Study of the Efficacy and Safety of SCH486757 in Subjects With Chronic Idiopathic Cough | 2007-11-29 | due-trials |
| Reported results | 2006-002308-32 | A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and High D... | 2011-02-28 | due-trials |
| Reported results | 2006-002309-30 | A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and High D... | 2010-07-27 | due-trials |
| Reported results | 2006-002488-20 | Studio Multicentrico randomizzato in doppio cieco per valutare la sicurezza e l'efficacia dell'aggiunta di sitagliptin MK 0431 in pazienti affetti da diabete mellito di tipo 2 in trattamento con metfo... | 2008-05-27 | due-trials |
| Reported results | 2006-002543-92 | A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 | 2008-11-18 | due-trials |
| Reported results Terminated | 2006-002544-28 | A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) | 2008-11-13 | due-trials |
| Reported results Terminated | 2006-002571-40 | A randomized, double-blind, active and placebo controlled trial to compare the relative analgesic efficacy and safety of a single intravenous dose of Org 28611 3.0 µg/kg, morphine sulfate 0.12 mg/kg, ... | 2007-08-22 | due-trials |
| Reported results | 2006-002669-38 | A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) | 2007-12-05 | due-trials |
| Reported results | 2006-002670-22 | Comparación de la eficacia y la seguridad del infliximab, en monoterapia o en combinación con azatioprina, y la azatioprina en monoterapia en la colitis ulcerosa activa de moderada a grave (1.ª parte)... | 2010-02-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-002791-18 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare... | 2009-08-12 | bad-data |
| Reported results | 2006-002809-31 | "Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:... | 2011-07-25 | due-trials |
| Reported results | 2006-002942-12 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Diseas... | 2011-12-23 | due-trials |
| Reported results | 2006-003080-31 | A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a st... | 2008-10-24 | due-trials |
| Reported results | 2006-003107-39 | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin | 2010-08-18 | due-trials |
| Reported results | 2006-003109-23 | A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Na ve HIV-Infected Patients, Each in Co... | 2012-02-24 | due-trials |
| Reported results | 2006-003169-15 | "Estudio de fase 2 de temozolomida (SCH 52365) en sujetos con neoplasias avanzadas del tracto respiratorio y digestivo seleccionados por metilación del promotor de la O6-metil-guanina-ADN metiltransfe... | 2009-06-11 | due-trials |
| Reported results Terminated | 2006-003463-31 | COVER- Registro de observación continua tras exposición Vicriviroc (VCV) | 2010-09-03 | due-trials |
| Reported results | 2006-003512-22 | A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea... | 2008-11-19 | due-trials |
| Reported results | 2006-003648-46 | A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process | 2008-06-03 | due-trials |
| Reported results | 2006-003649-18 | A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process | 2008-02-19 | due-trials |
| Reported results | 2006-003650-20 | A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process | 2008-05-05 | due-trials |
| Reported results | 2006-003651-20 | A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids | 2010-08-20 | due-trials |
| Ongoing | 2006-003652-37 | A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) ... | not-yet-due | |
| Reported results | 2006-003811-36 | A phase III, randomized, double-blind, active-controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 µg Org 36286 (corifollitropin alfa) to induce m... | 2007-09-27 | due-trials |
| Reported results | 2006-003812-23 | Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) | 2008-10-21 | due-trials |
| Reported results | 2006-003813-42 | Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 | 2008-12-12 | due-trials |
| Reported results | 2006-003879-12 | Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma | 2012-03-23 | due-trials |
| Reported results | 2006-003881-32 | Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options | 2010-07-14 | due-trials |
| Reported results Terminated | 2006-003924-13 | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease | 2007-11-16 | due-trials |
| Reported results | 2006-004072-12 | A multi-center, randomized, parallel-group, safety assessor-blinded trial comparing efficacy and safety of 4.0 mg.kg-1 Org 25969, administered at T1 3-10% after continuous infusion of rocuronium, and ... | 2007-03-02 | due-trials |
| Reported results | 2006-004169-33 | A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (DISKUS®) Versus Mometasone Furoate/Formoterol Fumarate 200/10 m... | 2008-11-14 | due-trials |
| Reported results | 2006-004257-14 | A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine Wi... | 2007-10-02 | due-trials |
| Reported results | 2006-004259-40 | A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura | 2009-01-23 | due-trials |
| Reported results | 2006-004291-12 | '' A multi-national, multi-centre, double-blind,randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects... | 2009-12-11 | due-trials |
| Reported results Terminated | 2006-004366-14 | Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients | 2008-10-02 | due-trials |
| Reported results | 2006-004534-32 | A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol... | 2008-12-08 | due-trials |
| Reported results | 2006-004535-30 | A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | 2009-06-01 | due-trials |
| Reported results Terminated | 2006-004933-14 | A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 V... | 2007-02-22 | due-trials |
| Reported results | 2006-005051-15 | A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa... | 2008-10-13 | due-trials |
| Reported results | 2006-005096-17 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House blinding Conditions of MK-0633 in Patients With COPD | 2009-03-30 | due-trials |
| Reported results | 2006-005101-64 | A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK-0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | 2008-04-28 | due-trials |
| Reported results | 2006-005122-23 | A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma... | 2008-12-12 | due-trials |
| Reported results | 2006-005234-21 | A RANDOMIZED ACCEPTABILITY AND SAFETY STUDY OF THE TRANSFER FROM SUBUTEX TO SUBOXONE IN OPIOID- DEPENDENT SUBJECTS- SWITCH | 2009-05-28 | due-trials |
| Reported results | 2006-005235-14 | "Estudio aleatorizado de aceptabilidad y seguridad de la inducción con Suboxone en consumidores de heroína" A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users | 2009-12-10 | due-trials |
| Reported results | 2006-005268-19 | Lutropina alfa (Luveris®) en mitad de la fase folicular de la estimulación ovárica controlada (COS) en la edad reproductiva avanzada. Estudio clínico en fase II. | 2010-10-31 | due-trials |
| Reported results | 2006-005453-30 | A Phase 2 Randomized Study Investigating the Safety, Efficacy and Pharmacokinetics of Daptomycin 6 mg/kg and 8 mg/kg Versus Comparator in the Treatment of Subjects Undergoing Surgical Standard of Car... | 2010-06-23 | due-trials |
| Reported results | 2006-005513-35 | A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg... | 2008-03-30 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-005515-10 | "Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot... | 2014-02-10 | bad-data |
| Reported results | 2006-005585-40 | A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis. | 2008-12-20 | due-trials |
| Reported results | 2006-005592-17 | Caelyx® in Breast Cancer in the Elderly Pegylated Liposomal Doxorubicin (Caelyx®) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer | 2009-10-16 | due-trials |
| Reported results | 2006-005780-26 | Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c... | 2010-08-20 | due-trials |
| Reported results | 2006-005931-56 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus | 2009-01-23 | due-trials |
| Reported results | 2006-005956-34 | A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis | 2007-04-23 | due-trials |
| Reported results | 2006-006168-46 | Thorough QT/QTc study for Garenoxacin | 2007-04-24 | due-trials |
| Reported results | 2006-006187-35 | A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura. | 2008-01-11 | due-trials |
| Reported results | 2006-006219-56 | A multicentre, double-blind, randomised, parallel-group study to evaluate the efficacy, safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to achieve an... | 2008-05-31 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-006415-74 | A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension | 2011-03-31 | bad-data |
| Reported results | 2006-006417-32 | Vicriviroc en combinación con un régimen TAR optimizado en sujetos infectados por el VIH tratados previamente (VICTOR-E4) | 2010-10-26 | due-trials |
| Reported results | 2006-006497-17 | "A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole... | 2008-07-16 | due-trials |
| Reported results | 2006-006529-25 | Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C | 2014-10-13 | due-trials |
| Reported results | 2006-006601-83 | A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis. | 2007-10-31 | due-trials |
| Reported results | 2006-006686-17 | Evaluation of preference for a buprenorphine-based maintenance therapy, after a switch from buprenorphine alone (Subutex®) to the buprenorphine/naloxone combination (Suboxone®), in opioid-dependent pa... | 2007-12-21 | due-trials |
| Reported results | 2006-006843-29 | A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in ... | 2009-01-26 | due-trials |
| Reported results | 2007-000019-27 | A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control | 2008-08-15 | due-trials |
| Reported results | 2007-000037-19 | A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in... | 2010-08-06 | due-trials |
| Reported results | 2007-000145-35 | A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M... | 2009-10-27 | due-trials |
| Reported results | 2007-000343-10 | A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age | 2009-02-24 | due-trials |
| Reported results | 2007-000344-26 | A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj... | 2008-05-12 | due-trials |
| Reported results | 2007-000535-26 | SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO) | 2010-10-22 | due-trials |
| Reported results | 2007-000690-34 | A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess... | 2007-10-22 | due-trials |
| Reported results | 2007-000755-33 | Multicenter, open, pragmatic, randomized trial comparing the efficacy of 3 different lifestyle interventions after addition of sitagliptin to patients with type 2 diabetes mellitus who have inadequate... | 2009-11-19 | due-trials |
| Reported results Terminated | 2007-000783-25 | A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA... | 2009-04-21 | due-trials |
| Reported results | 2007-001116-22 | A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer | 2012-03-07 | due-trials |
| Reported results | 2007-001407-37 | A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure... | 2009-07-30 | due-trials |
| Reported results | 2007-001611-32 | A multi-center cardiac safety study of subjects who participated in Organon sponsored Phase 1 and Phase 2 completed and discontinued trials with Org 24448 (Protocols: 22601;22602;22603; 153001;153002;... | 2009-01-01 | due-trials |
| Reported results | 2007-001691-36 | A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control. | 2009-03-16 | due-trials |
| Reported results | 2007-001717-42 | A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID | 2009-11-19 | due-trials |
| Reported results | 2007-001771-11 | A Phase I Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Study the Safety, Efficacy, and Mechanism of Action of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitu... | 2009-02-24 | due-trials |
| Reported results | 2007-001959-19 | A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti- Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium... | 2009-06-05 | due-trials |
| Reported results | 2007-002017-39 | A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta... | 2008-10-10 | due-trials |
| Reported results | 2007-002218-21 | A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and Metf... | 2010-01-27 | due-trials |
| Reported results | 2007-002383-95 | A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia | 2009-10-01 | due-trials |
| Reported results | 2007-002515-75 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus | 2008-08-05 | due-trials |
| Reported results | 2007-002516-26 | A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ... | 2008-06-16 | due-trials |
| Reported results | 2007-002523-33 | A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study with Org 50081 in elderly subjects with chronic primary insomnia | 2009-12-21 | due-trials |
| Reported results | 2007-002667-28 | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho... | 2009-03-27 | due-trials |
| Reported results | 2007-002693-66 | 1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-... | 2017-02-01 | due-trials |
| Reported results | 2007-002911-18 | Comparison of the T4/T1 ratio measured by means of the TOF-Watch® SX with the reappearance of T4 measured by means of a peripheral nerve stimulator in adult subjects receiving 4.0 mg.kg-1 sugammadex a... | 2008-02-07 | due-trials |
| Reported results Terminated | 2007-003133-16 | Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects | 2010-07-09 | due-trials |
| Reported results | 2007-003148-31 | A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection. | 2009-04-24 | due-trials |
| Reported results | 2007-003361-40 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK-0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine | 2008-04-08 | due-trials |
| Reported results | 2007-003428-38 | A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma | 2008-02-01 | due-trials |
| Reported results | 2007-003462-18 | A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas | 2014-09-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-003528-39 | "A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (... | 2016-07-08 | bad-data |
| Reported results | 2007-003529-26 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialy... | 2011-03-14 | due-trials |
| Reported results | 2007-003548-32 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina... | 2011-03-16 | due-trials |
| Reported results | 2007-003636-35 | A randomized long-term safety study of Org 50081 in elderly outpatients with chronic primary insomnia examining the effects of 1.5 mg or 3.0 mg of Org 50081 | 2010-02-19 | due-trials |
| Exempt, with results Terminated | 2007-003674-26 | A Phase I Dose Escalation of MK-0457 in Combination With Dasatinib in Patients With Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. | 2008-07-30 | not-yet-due |
| Reported results | 2007-003684-41 | A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in... | 2009-01-08 | due-trials |
| Reported results | 2007-003852-13 | A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL™ t... | 2009-05-20 | due-trials |
| Reported results | 2007-003971-38 | An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast | 2011-10-28 | due-trials |
| Reported results | 2007-004018-15 | A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati... | 2011-08-18 | due-trials |
| Reported results | 2007-004020-20 | A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age | 2010-01-05 | due-trials |
| Reported results | 2007-004043-30 | A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr... | 2009-06-29 | due-trials |
| Reported results | 2007-004137-42 | A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien... | 2009-10-23 | due-trials |
| Reported results | 2007-004331-27 | A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of SCH 900340 5% Solution Compared with Vehicle Administered Topically in the Treatment of Distal ... | 2010-02-12 | due-trials |
| Reported results | 2007-004448-60 | A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc... | 2009-03-29 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-004645-15 | Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia | 2015-07-10 | bad-data |
| Reported results | 2007-004683-45 | An exploratory study of mometasone furoate nasal spray in patients with moderate-severe persistent allergic rhinitis and intermittent asthma: effects on the quality of life evaluated with the Rhinasth... | 2009-05-11 | due-trials |
| Reported results | 2007-004879-19 | A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared With Placebo, on Exercise-Induced Bronchoconstriction (EIB) in P... | 2010-03-26 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-004980-23 | Double-Blind evaluation of the safety and efficacy of Quadriderme cream (betamethasone dipropionate, clotrimazole and gentamicin sulphate ) compare with betamethasone dipropionate combined with gentam... | bad-data | |
| Reported results | 2007-005151-42 | "Estudio fase 3 de Seguridad y Eficacia de Boceprevir en pacientes con Hepatitis C Crónica genotipo 1 que recayeron tras el tratamiento previo con Peginterferón/Ribavirina". "A Phase 3 Safety and Eff... | 2010-04-15 | due-trials |
| Reported results | 2007-005236-92 | A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia. | 2009-11-19 | due-trials |
| Reported results | 2007-005237-10 | A twenty-six weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed clinical trial protocol 21106. | 2010-04-13 | due-trials |
| Reported results | 2007-005341-38 | "Estudio para determinar la actividad de SCH 717454 en sujetos con Osteosarcoma o Sarcoma de Ewing que hayan recaído después de terapia sistémica estándar." "A Study to Determine the Activity of SCH ... | 2013-08-31 | due-trials |
| Reported results Terminated | 2007-005491-14 | TEMOZOLOMIDE IN METASTATIC BREAST CANCER PATIENTS AT HIGH RISK OF BRAIN RECURRENCE: IMPACT ON THE INCIDENCE OF BRAIN METASTASES | 2010-06-30 | due-trials |
| Reported results | 2007-005508-42 | "Estudio Fase 3 de Seguridad y Eficacia de Boceprevir en Pacientes con Hepatitis C Crónica Genotipo 1 No Tratados Previamente." "A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untre... | 2010-05-19 | due-trials |
| Reported results | 2007-005615-26 | Safety of SCH 527123 in Subjects With Neutrophilic Asthma | 2009-02-20 | due-trials |
| Reported results | 2007-005793-31 | A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic ... | 2008-08-18 | due-trials |
| Reported results | 2007-005839-28 | A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a... | 2017-11-23 | due-trials |
| Reported results | 2007-005941-39 | An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA) for Patients With Recurrent Non-Small Cell Lung Cancer. | 2012-02-13 | due-trials |
| Reported results | 2007-006074-28 | A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metfo... | 2009-02-04 | due-trials |
| Reported results | 2007-006097-28 | Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared with Inhaled Corticosteroid Therapy Alone in Patients with Chronic As... | 2008-12-22 | due-trials |
| Reported results | 2007-006304-37 | A multi-center, randomized, parallel-group, active-controlled, safety-assessor blinded trial, comparing the efficacy and safety of 2.0 mg.kg-1 sugammadex with 50 μg.kg-1 neostigmine administered at re... | 2010-09-01 | due-trials |
| Reported results | 2007-006934-33 | A single center, open-label trial in subjects with severe renal impairment evaluating the dialysability of the sugammadex-rocuronium complex | 2009-07-08 | due-trials |
| Reported results | 2007-006935-29 | A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired re... | 2010-03-15 | due-trials |
| Reported results | 2007-007162-38 | A multi-center, open label trial, to show efficacy and safety of 4.0 mg.kg-1 sugammadex administered at a depth of neuromuscular blockade of 1-2 PTC induced by rocuronium in Chinese and European ASA I... | 2010-08-25 | due-trials |
| Reported results | 2007-007723-40 | A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled, Period Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stabl... | 2009-09-02 | due-trials |
| Reported results | 2007-007951-14 | A multi-center, randomized, parallel-group, comparative, active-controlled, safety-assessor blinded trial in adult subjects comparing the efficacy and safety of sugammadex administered at 1-2 PTC with... | 2009-05-04 | due-trials |
| Reported results | 2008-000149-72 | A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient... | 2010-04-14 | due-trials |
| Reported results | 2008-000150-12 | A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa... | 2012-09-10 | due-trials |
| Reported results | 2008-000422-39 | "Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti... | 2011-05-12 | due-trials |
| Reported results | 2008-000454-12 | A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. | 2011-04-04 | due-trials |
| Reported results Terminated | 2008-000465-37 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy... | 2008-07-14 | due-trials |
| Reported results | 2008-000634-53 | A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy | 2012-07-09 | due-trials |
| Reported results | 2008-000982-51 | Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial | 2011-11-03 | due-trials |
| Reported results | 2008-001153-17 | Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination... | 2010-07-20 | due-trials |
| Reported results | 2008-001226-14 | A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine | 2009-01-16 | due-trials |
| Reported results | 2008-001971-30 | A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer | 2011-05-10 | due-trials |
| Reported results Terminated | 2008-002079-28 | A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and... | 2008-11-06 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-002119-42 | A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer Spanish titl... | bad-data | |
| Reported results Terminated | 2008-002120-29 | A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer | 2010-01-18 | due-trials |
| Reported results | 2008-002121-36 | A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa... | 2010-06-28 | due-trials |
| Exempt, with results | 2008-002142-38 | A phase I, single center, open-label parallel group trial to compare the pharmacokinetics of NOMAC between healthy female adolescents (aged 14-17 years) and healthy female adults (aged 18-50 years) af... | 2009-05-18 | not-yet-due |
| Reported results Terminated | 2008-002209-38 | A multicenter, randomized, double-blind, placebo-controlled study of the hemodynamic effects of rolofylline injectable emulsion in the treatment of patients with heart failure | 2009-03-06 | due-trials |
| Reported results | 2008-002518-23 | A randomized, safety-assessor blinded trial comparing 4.0 mg.kg-1 sugammadex with placebo in adult subjects scheduled for surgery requiring profound neuromuscular blockade | 2009-06-12 | due-trials |
| Reported results | 2008-002733-70 | "Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra... | 2011-05-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-003178-17 | A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery. | 2013-03-12 | bad-data |
| Reported results | 2008-003377-41 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, with Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the Cogstate Computerized Neu... | 2010-04-14 | due-trials |
| Reported results | 2008-003379-28 | A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK-0663/Etoricoxib and Ibuprofen in the Treatment of ... | 2010-12-14 | due-trials |
| Reported results | 2008-003640-11 | A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | 2011-03-25 | due-trials |
| Reported results | 2008-003752-30 | An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma | 2016-06-30 | due-trials |
| Reported results | 2008-003753-33 | An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma | 2012-04-09 | due-trials |
| Reported results | 2008-003780-38 | A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD | 2011-11-11 | due-trials |
| Reported results | 2008-003864-20 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in Adu... | 2011-05-20 | due-trials |
| Reported results | 2008-003923-21 | A Phase III, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0826/Ertapenem and Meropenem in Patients with Complicated Urinary Tract Infections | 2009-06-08 | due-trials |
| Reported results | 2008-004095-43 | A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patie... | 2009-08-24 | due-trials |
| Reported results Terminated | 2008-004119-36 | Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects with Severe Asthma | 2010-01-09 | due-trials |
| Reported results | 2008-004504-31 | A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on ... | 2011-03-21 | due-trials |
| Reported results | 2008-004555-30 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia | 2009-09-21 | due-trials |
| Reported results | 2008-004556-71 | A Single-Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders tPeginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies | 2012-12-07 | due-trials |
| Reported results | 2008-004578-42 | An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopau... | 2014-11-11 | due-trials |
| Reported results | 2008-004686-26 | A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence | 2010-03-11 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-004732-20 | A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK-0954/Losartan Potassium in Pediatric Patients With Hypertension | 2012-08-14 | bad-data |
| Reported results | 2008-004760-39 | A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon... | 2010-10-19 | due-trials |
| Reported results Terminated | 2008-004831-39 | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-... | 2010-05-24 | due-trials |
| Reported results | 2008-004864-38 | A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C | 2012-10-01 | due-trials |
| Reported results | 2008-004867-21 | A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK-0663/Etoricoxib in the Treatment of Pain after Abdominal Hysterectomy | 2010-07-05 | due-trials |
| Reported results | 2008-004881-16 | Efecto de la acadesina sobre los eventos adversos cardiovasculares y cerebrovasculares, clínicamente significativos, en pacientes de alto riesgo que se someten a cirugía de derivación aortocoronaria ... | 2010-10-04 | due-trials |
| Reported results | 2008-004953-14 | A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Ezetimibe 10 mg Added on to Rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg Versus Up-Titration Ro... | 2010-05-10 | due-trials |
| Reported results | 2008-005002-40 | "Estudio aleatorizado, doble ciego, con control activo, multicéntrico en pacientes con hipercolesterolemia primaria y alto riesgo cardiovascular y no controlados adecuadamente con Atorvastatina 20 mg:... | 2010-09-22 | due-trials |
| Reported results Terminated | 2008-005061-57 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose- Ranging Study of MK-0633 in Adult Patients with Chronic Asthma | 2009-06-15 | due-trials |
| Reported results | 2008-005318-35 | A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence | 2010-06-25 | due-trials |
| Reported results | 2008-005616-40 | A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes... | 2010-03-02 | due-trials |
| Reported results Terminated | 2008-005817-23 | A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control | 2009-08-20 | due-trials |
| Reported results | 2008-005874-11 | A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fra... | 2012-10-18 | due-trials |
| Reported results | 2008-005942-22 | A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations | 2012-08-29 | due-trials |
| Reported results Terminated | 2008-006018-97 | A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomni... | 2009-12-26 | due-trials |
| Reported results | 2008-006215-20 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin | 2010-05-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-006271-70 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fam... | 2012-04-13 | bad-data |
| Reported results | 2008-006719-20 | TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | 2015-03-30 | due-trials |
| Reported results | 2008-006720-62 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyc... | 2010-11-11 | due-trials |
| Reported results | 2008-007504-28 | 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma | 2015-01-29 | due-trials |
| Reported results | 2008-007689-52 | A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A... | 2011-03-02 | due-trials |
| Reported results | 2008-008006-46 | A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) | 2010-10-22 | due-trials |
| Reported results | 2008-008257-30 | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos... | 2011-09-21 | due-trials |
| Reported results | 2008-008283-26 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topira... | 2009-10-22 | due-trials |
| Reported results | 2008-008354-23 | CONSERV TM – 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide’s Effect on Reducing Surgical Blood Loss Volume) – A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects E... | 2010-05-31 | due-trials |
| Reported results | 2009-009517-18 | A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha... | 2010-07-12 | due-trials |
| Reported results | 2009-010108-27 | A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclome... | 2012-11-20 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-010110-30 | A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate / Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared ... | 2017-12-04 | bad-data |
| Reported results Terminated | 2009-010904-27 | A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Wh... | 2010-05-26 | due-trials |
| Exempt, with results Terminated | 2009-011101-16 | Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination with Different Treatment Regimens in Subjects with Advanced Solid Tumors (Phase 1b/2; Protocol No. P04722) | 2011-06-07 | not-yet-due |
| Reported results | 2009-011137-26 | An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-na�ve subjects with rheumatoid arthritis (P... | 2012-02-02 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-011617-25 | A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Pre... | 2021-08-31 | bad-data |
| Reported results | 2009-011920-69 | A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fractu... | 2009-04-10 | due-trials |
| Reported results Terminated | 2009-012000-10 | A Phase II Randomised, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK 7009 when administered concomitantly with Pegylated Interferon and Ribavi... | 2010-09-08 | due-trials |
| Reported results | 2009-012121-11 | A randomized, multicenter, explorative trial to explore the safety, acceptability and vaginal bleeding pattern of three doses of an etonogestrel-releasing medicated intrauterine system (ENG-MIUS) vers... | 2011-07-26 | due-trials |
| Reported results | 2009-012772-27 | "Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de libera... | 2011-06-14 | due-trials |
| Reported results | 2009-012782-63 | Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anem... | 2011-10-26 | due-trials |
| Reported results Terminated | 2009-012926-35 | A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women with Osteoporosis | 2010-10-20 | due-trials |
| Reported results | 2009-013053-15 | "Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic... | 2013-05-29 | due-trials |
| Reported results Terminated | 2009-013286-26 | A Phase IIb, Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive... | 2010-06-02 | due-trials |
| Reported results Terminated | 2009-013552-72 | A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0566... | 2013-07-16 | due-trials |
| Reported results Terminated | 2009-014657-32 | "A Phase IIa Randomized, Placebo-Controlled, Parallel Group, Clinical Trial to Study the Efficacy and Safety of MK-2866 in Women with Moderate to Severe Chronic Obstructive Pulmonary Disease Participa... | 2010-02-25 | due-trials |
| Reported results | 2009-014729-18 | "A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Po... | 2011-06-16 | due-trials |
| Exempt, with results | 2009-015103-58 | A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers | 2011-01-05 | not-yet-due |
| Reported results | 2009-015161-31 | A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P... | 2012-12-20 | due-trials |
| Reported results | 2009-015162-57 | A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153) | 2013-07-16 | due-trials |
| Reported results | 2009-015247-16 | A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A... | 2012-10-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-015500-26 | "A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Par... | 2015-11-30 | bad-data |
| Reported results | 2009-015565-31 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia | 2011-08-01 | due-trials |
| Reported results | 2009-015773-12 | "Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacie... | 2011-02-01 | due-trials |
| Reported results | 2009-015798-11 | Ensayo de fase III, aleatorizado, controlado con un fármaco de comparación activo, con doble enmascaramiento, de doce semanas de duración, para comparar la eficacia y la seguridad de MK-2452 (0,0015%... | 2010-09-17 | due-trials |
| Reported results | 2009-016070-33 | A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Wom... | 2010-08-24 | due-trials |
| Reported results | 2009-016218-26 | A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE... | 2011-06-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-016374-32 | "Ensayo Clínico Mundial, Aleatorizado, Doble Ciego, Controlado con Placebo, con Grupos Paralelos para Evaluar la Seguridad y Eficacia de Rizatriptán en el Tratamiento de las Crisis de Migraña en Niños... | 2011-05-06 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-016375-30 | "Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos." // "A Worldwide, Open L... | 2011-04-29 | bad-data |
| Reported results Terminated | 2009-016376-76 | A Phase II Extension of a Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidne... | 2010-04-01 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-016587-36 | Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®) | bad-data | |
| Exempt, with results | 2009-017054-12 | A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer | 2011-06-13 | not-yet-due |
| Reported results | 2009-017272-24 | Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis | 2012-10-24 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-017288-40 | A Randomized, Open-Label, Comparative, Multicenter Trial to Compare the Effects on Metabolic Parameters of Two NOMAC-E2 Batches (Pivotal Phase III and Commercial Batch) and a Monophasic COC Containing... | bad-data | |
| Trial is partly outside EEC, and reported results | 2009-017971-10 | An 8-Week, Placebo-Controlled, Double-Blind, Randomized, Fixed- Dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia | 2013-04-01 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-018038-12 | A 26-Week, Multi-Center, Open-Label, Flexible Dose, Long-Term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia | 2013-10-07 | bad-data |
| Reported results | 2010-018318-62 | A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylu... | 2012-01-19 | due-trials |
| Reported results | 2010-018407-28 | A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerba... | 2014-09-09 | due-trials |
| Reported results | 2010-018408-96 | A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P056... | 2015-03-06 | due-trials |
| Reported results | 2010-018409-13 | A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experiencing ... | 2014-05-28 | due-trials |
| Reported results | 2010-018410-78 | A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed with Bipolar 1 Disorder who Completed Protocol P05691 (formerly 041044) (Phase3B, Pr... | 2014-11-21 | due-trials |
| Reported results | 2010-018413-30 | "Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud... | 2011-12-07 | due-trials |
| Reported results | 2010-018414-69 | "Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud... | 2011-11-08 | due-trials |
| Reported results | 2010-019288-13 | A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related ... | 2011-04-08 | due-trials |
| Reported results | 2010-019454-41 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1 | 2013-07-22 | due-trials |
| Reported results | 2010-019775-29 | "Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13 en lactantes sanos";"A Multic... | 2012-07-31 | due-trials |
| Reported results | 2010-019867-13 | "A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br... | 2013-10-15 | due-trials |
| Reported results | 2010-019871-31 | A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with R... | 2014-08-07 | due-trials |
| Reported results | 2010-019872-65 | A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients... | 2014-11-12 | due-trials |
| Reported results | 2010-020112-11 | A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037) | 2013-04-16 | due-trials |
| Reported results | 2010-020150-34 | "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic... | 2015-12-23 | due-trials |
| Reported results | 2010-020234-26 | A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellit... | 2012-10-31 | due-trials |
| Exempt, with results | 2010-020832-20 | An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356) | 2011-05-23 | not-yet-due |
| Reported results | 2010-021367-32 | A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation | 2011-11-23 | due-trials |
| Reported results Terminated | 2010-021627-27 | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lip... | 2013-01-11 | due-trials |
| Reported results | 2010-022121-15 | A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder | 2013-10-10 | due-trials |
| Reported results | 2010-022168-11 | A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Stru... | 2011-09-30 | due-trials |
| Reported results | 2010-022193-13 | "Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control... | 2013-04-01 | due-trials |
| Trial is outside EEC, and reported results | 2010-022647-38 | Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107) | bad-data | |
| Trial is outside EEC, and reported results | 2010-022648-19 | A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder | bad-data | |
| Reported results | 2010-023156-89 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I... | 2017-04-11 | due-trials |
| Reported results | 2010-023452-87 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEP... | 2013-09-04 | due-trials |
| Reported results | 2010-023453-11 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEP... | 2013-05-29 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-023498-20 | Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) | 2014-01-21 | bad-data |
| Completed, but no date, and reported results | 2010-023580-18 | Ensayo clínico fase II, de cetuximab en cáncer colorrectal metastático refractario con K-RAS mutado y genotipos FcyRII/IIIa favorables Phase II clinical study of cetuximab in refractory colorectal can... | bad-data | |
| Reported results | 2010-023759-27 | A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T... | 2012-04-30 | due-trials |
| Reported results | 2010-023939-42 | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Prim... | 2011-11-14 | due-trials |
| Reported results Terminated | 2010-024260-17 | A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1. Studio di Fase ... | 2014-01-21 | due-trials |
| Reported results | 2011-000311-34 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects with Active Axial Spondyloarthritis (Phase 3b, Protocol No. P07642,... | 2015-01-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000651-16 | A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o... | 2013-08-16 | bad-data |
| Reported results | 2011-000656-42 | A 66-Week Extension to: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding, Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadeq... | 2013-04-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000729-55 | A Phase I Study of Ridaforolimus in Paediatric Patients with Advanced Solid Tumours | 2018-05-25 | bad-data |
| Reported results | 2011-000759-18 | A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alf... | 2015-03-10 | due-trials |
| Reported results Terminated | 2011-001007-12 | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patient... | 2011-11-14 | due-trials |
| Reported results | 2011-001201-27 | A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blockade ... | 2012-09-26 | due-trials |
| Reported results | 2011-001345-32 | A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects | 2015-06-08 | due-trials |
| Reported results | 2011-002119-27 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF INTRAVENOUS CXA-201 WITH THAT OF MEROPENEM IN COMPLICATED INTRAABDOMINAL INFECTIONS | 2013-09-10 | due-trials |
| Reported results | 2011-002120-41 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF INTRAVENOUS CXA-201 WITH THAT OF MEROPENEM IN COMPLICATED INTRAABDOMINAL INFECTIONS | 2013-10-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-002142-13 | A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ... | 2016-10-11 | bad-data |
| Reported results | 2011-002313-11 | A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease | 2013-02-26 | due-trials |
| Trial is outside EEC, and reported results | 2011-002348-28 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years | bad-data | |
| Trial is outside EEC, and reported results | 2011-002349-36 | An Open-Label Single-Dose Study to Evaluate the Pediatric Palatability of Maxalt Oral Disintegrating Tablets | bad-data | |
| Completed, but no date, and reported results | 2011-002508-34 | Evaluate adherence to treatment with Glucophage sachets versus tablets in diabetes type 2 patients, previously treated with metformin tablets Evaluar la adherencia al tratamiento con Dianben sobres... | bad-data | |
| Trial is partly outside EEC, and reported results | 2011-002528-42 | A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq... | 2019-10-09 | bad-data |
| Reported results | 2011-002529-23 | "A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P... | 2019-10-17 | due-trials |
| Reported results | 2011-002533-18 | 52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder | 2013-10-10 | due-trials |
| Reported results | 2011-002803-13 | A Randomised, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Canc... | 2016-08-08 | due-trials |
| Reported results | 2011-002860-26 | A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of Acut... | 2013-01-10 | due-trials |
| Reported results | 2011-003151-20 | A Randomised, Placebo-Controlled, Parellel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 with a long term double-blind extension in Subjects with Mild to Moderate Alzheimer's Disease | 2017-04-14 | due-trials |
| Reported results Terminated | 2011-003299-36 | A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomita... | 2012-05-01 | due-trials |
| Reported results Terminated | 2011-003399-36 | A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubicin... | 2012-01-26 | due-trials |
| Exempt, with results | 2011-003407-38 | A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Paediatric Patients with Advanced Solid Tumours | 2013-09-25 | not-yet-due |
| Trial is outside EEC, and reported results | 2011-003433-33 | A Single Dose Biocomparison Study to Assess two Pediatric Formulations of MK-8669 to the Provisional Market Formulation in Healthy Subjects | bad-data | |
| Reported results Terminated | 2011-003600-20 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Contr... | 2012-12-04 | due-trials |
| Reported results | 2011-003938-14 | A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults (Phase 3; Protocol No. MK- 5592-069) | 2019-09-10 | due-trials |
| Reported results | 2011-003971-12 | A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus? in Subjects With Type 1 Diabetes Mellitus. Estudio clínico de fase III para estudiar la seguridad y eficac... | 2015-11-18 | due-trials |
| Reported results | 2011-004525-27 | A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Witho... | 2018-11-13 | due-trials |
| Reported results | 2011-004542-18 | A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and Prevna... | 2013-02-15 | due-trials |
| Reported results | 2011-004590-90 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d... | 2015-01-19 | due-trials |
| Reported results | 2011-004622-96 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes ... | 2013-06-07 | due-trials |
| Reported results | 2011-004994-94 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-341... | 2015-05-22 | due-trials |
| Reported results | 2011-005186-20 | A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL) | 2014-12-22 | due-trials |
| Reported results | 2011-005200-15 | A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder. | 2013-09-03 | due-trials |
| Reported results Terminated | 2011-005514-10 | A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce t... | 2017-02-01 | due-trials |
| Reported results | 2011-005686-20 | ?A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with ... | 2014-08-12 | due-trials |
| Reported results | 2011-005707-32 | A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with C... | 2015-07-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-006006-27 | A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the ... | 2016-09-26 | bad-data |
| Reported results | 2012-000252-34 | A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea | 2015-03-20 | due-trials |
| Reported results | 2012-000317-36 | A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancer... | 2014-12-09 | due-trials |
| Reported results | 2012-000335-11 | A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Pat... | 2018-03-15 | due-trials |
| Reported results | 2012-000439-17 | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ... | 2013-09-13 | due-trials |
| Reported results | 2012-000642-35 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects with Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast | 2014-05-05 | due-trials |
| Reported results Terminated | 2012-000643-27 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma | 2014-07-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-000972-40 | A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation. | bad-data | |
| Trial is partly outside EEC, and reported results | 2012-001258-25 | A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing i... | 2015-04-08 | bad-data |
| Reported results | 2012-001377-88 | A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), F... | 2021-10-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-001443-49 | A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia | 2013-01-11 | bad-data |
| Reported results | 2012-001573-93 | Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment... | 2016-03-18 | due-trials |
| Reported results | 2012-001611-23 | A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM) | 2014-03-25 | due-trials |
| Reported results | 2012-001718-41 | A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of ... | 2014-11-03 | due-trials |
| Reported results | 2012-001855-38 | A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 using an Environmental Exposure Chamber in Subjects with House Dust induced Allergi... | 2013-08-27 | due-trials |
| Reported results | 2012-001868-29 | A Phase III, Randomized, Double-Blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a fixed-dose combination [FDC] of sitagliptin and simvastatin) for the Treatment of Patients With Ty... | 2013-11-01 | due-trials |
| Reported results | 2012-001886-33 | Randomized, Controlled, Parallel Group, Double Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Factor... | 2014-04-29 | due-trials |
| Reported results | 2012-002181-12 | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in S... | 2013-10-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002232-85 | A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Pr... | 2021-03-31 | bad-data |
| Reported results | 2012-002309-23 | A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Melli... | 2015-01-26 | due-trials |
| Reported results | 2012-002332-85 | A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney ... | 2016-01-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-002340-24 | A Phase IIb, Partially-Blinded Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the... | 2016-11-21 | bad-data |
| Reported results | 2012-002414-39 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus Studio multicentrico... | 2017-03-22 | due-trials |
| Reported results Terminated | 2012-002434-37 | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patie... | 2014-02-04 | due-trials |
| Reported results | 2012-002449-40 | A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 µg nomegestrol ac... | 2013-09-23 | due-trials |
| Reported results | 2012-002458-21 | Open-label, Phase 4 Study, investigating the Incidence of Extra-Articular Manifestations in Subjects with Ankylosing Spondylitis treated with Golimumab Open-label fase 4 onderzoek, dat het optreden... | 2015-04-30 | due-trials |
| Reported results | 2012-002459-41 | A multicenter, randomized, partially-blinded, Phase IIb dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings releasi... | 2013-10-15 | due-trials |
| Reported results | 2012-002499-15 | A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia | 2015-11-11 | due-trials |
| Reported results | 2012-002523-14 | A Phase 2, Open-Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | 2018-10-22 | due-trials |
| Reported results | 2012-002612-10 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Ina... | 2014-12-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002758-22 | A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-... | 2014-08-04 | bad-data |
| Completed, but no date, and reported results Terminated | 2012-002771-33 | An open label study assessing SVR and Viral Resistance profile with Boceprevir plus PEG-IFN plus Ribavirin triple therapy in HCV-1 infected patients with insulin resistance who have failed PEG-IFN plu... | bad-data | |
| Reported results | 2012-002772-13 | A multi-centre single-arm study to evaluate the efficacy and safety of BOCEPREVIR 44 weeks in addition to standard of care (SOC) in previously treatment failure (relapser, non-responders, both partial... | 2015-11-17 | due-trials |
| Reported results | 2012-002862-11 | A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No... | 2018-06-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-003030-17 | Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma | 2019-01-31 | bad-data |
| Reported results | 2012-003110-14 | A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or With... | 2014-10-29 | due-trials |
| Reported results Terminated | 2012-003140-68 | A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients | 2014-01-17 | due-trials |
| Reported results | 2012-003333-42 | A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Riba... | 2014-01-29 | due-trials |
| Reported results | 2012-003340-72 | A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection | 2014-03-12 | due-trials |
| Reported results | 2012-003354-89 | A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection | 2015-05-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-003414-14 | A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents Treated with Glucocorticoids | 2016-09-02 | bad-data |
| Trial is partly outside EEC, and reported results | 2012-003447-29 | A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO-SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. A daptomi... | 2016-01-20 | bad-data |
| Reported results | 2012-003626-24 | A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | 2015-06-19 | due-trials |
| Reported results | 2012-003670-11 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Contr... | 2016-03-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-004035-23 | A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Rel... | 2019-10-09 | bad-data |
| Completed, but no date, and reported results Terminated | 2012-004190-12 | Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera™ in Patients with Advanced CD20-Positive Follicular Lymphoma. Studio multicentrico, random... | bad-data | |
| Reported results | 2012-004303-12 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects with Type 2 Diabetes Mellitus and Inadequat... | 2015-09-14 | due-trials |
| Reported results | 2012-004391-19 | A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer | 2020-09-30 | due-trials |
| Reported results | 2012-004907-10 | A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanc... | 2019-06-03 | due-trials |
| Reported results Terminated | 2012-005170-65 | A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Tri... | 2014-06-18 | due-trials |
| Reported results | 2012-005542-38 | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Du... | 2018-04-17 | due-trials |
| Reported results | 2013-000059-42 | A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared with the Addition of Sitagliptin in Subjects with Type 2 Diabetes Melli... | 2014-11-17 | due-trials |
| Reported results | 2013-000161-36 | Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) Estudio de fase 2 demostrativo preliminar de la actividad... | 2015-01-12 | due-trials |
| Reported results | 2013-000301-23 | A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappr... | 2014-04-03 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-000864-28 | A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ... | 2016-12-20 | bad-data |
| Trial is partly outside EEC, and reported results | 2013-001314-15 | A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Prea... | 2017-07-24 | bad-data |
| Trial is outside EEC, and reported results | 2013-001448-75 | A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium di... | bad-data | |
| Reported results | 2013-001526-26 | An Observational Follow-Up Study for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic... | 2016-07-23 | due-trials |
| Reported results Terminated | 2013-001637-40 | Switching from regimens consisting of a RTV -boosted protease inhibitor plus TDF/ FTC to a combination of RAltegravir pluis NevIrapine and IAmivudine in HIV patients with suppressed viremia and and i... | 2017-07-10 | due-trials |
| Completed, but no date, and reported results Terminated | 2013-001740-54 | A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Op... | bad-data | |
| Reported results | 2013-001939-47 | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 4... | 2016-12-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-002084-26 | A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive C... | bad-data | |
| Reported results | 2013-002169-21 | A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects with Chronic Hepatitis C Genot... | 2014-12-04 | due-trials |
| Reported results | 2013-002518-11 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLI... | 2019-12-27 | due-trials |
| Reported results | 2013-002519-90 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subject... | 2016-07-28 | due-trials |
| Reported results | 2013-003290-95 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLIT... | 2017-08-03 | due-trials |
| Reported results | 2013-003582-34 | A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With th... | 2017-04-18 | due-trials |
| Reported results | 2013-003587-31 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellit... | 2016-09-28 | due-trials |
| Reported results | 2013-003697-26 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Sub... | 2016-06-06 | due-trials |
| Reported results | 2013-003698-82 | A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin Alon... | 2016-06-06 | due-trials |
| Reported results | 2013-003831-31 | A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection... | 2016-11-21 | due-trials |
| Reported results | 2013-003858-25 | A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Dise... | 2015-09-02 | due-trials |
| Reported results | 2013-004154-22 | A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia | 2018-06-22 | due-trials |
| Reported results | 2013-004213-41 | A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Direct ... | 2015-05-04 | due-trials |
| Completed, but no date, and reported results Terminated | 2013-004423-36 | Randomized, parallel group, controlled trial to compare two different “NMB + reversal” strategies in adult obese patients underwent laparoscopic abdominal surgery (Phase 4; Protocol No. MK-8616-104-00... | bad-data | |
| Reported results | 2013-004583-56 | Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis | 2016-05-25 | due-trials |
| Reported results | 2014-000137-22 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection | 2015-09-06 | due-trials |
| Reported results | 2014-000323-25 | A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer | 2021-05-27 | due-trials |
| Reported results | 2014-000342-30 | A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who ... | 2015-05-22 | due-trials |
| Reported results | 2014-000343-32 | A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who a... | 2018-12-04 | due-trials |
| Reported results | 2014-000656-29 | Preference for a prefilled syringe or Smartject™ device for delivering SIMPONI (golimumab) in patients suffering from moderate to severe ulcerative colitis | 2015-10-05 | due-trials |
| Reported results | 2014-000672-25 | A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis... | 2015-06-16 | due-trials |
| Reported results | 2014-000824-12 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin... | 2015-06-19 | due-trials |
| Completed, but no date, and reported results Terminated | 2014-001030-29 | A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults | bad-data | |
| Reported results | 2014-001049-25 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-049717... | 2016-02-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001127-69 | A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once ... | 2023-03-06 | bad-data |
| Reported results | 2014-001280-13 | An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled i... | 2020-03-19 | due-trials |
| Reported results | 2014-001281-94 | An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients with β-Thalassemia Previously Enrolled in Study A536-04 | 2020-04-28 | due-trials |
| Reported results | 2014-001473-14 | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastati... | 2022-09-12 | due-trials |
| Reported results | 2014-001749-26 | A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer | 2022-08-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-001783-34 | A Phase III, Randomised, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nause... | 2017-02-24 | bad-data |
| Reported results | 2014-002009-40 | A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer | 2020-10-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-002206-20 | A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer | 2022-02-18 | bad-data |
| Reported results | 2014-002208-26 | A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17?-estradiol) vaginal ring and the levonorgestrel-eth... | 2016-10-06 | due-trials |
| Reported results | 2014-002356-27 | A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood ... | 2016-06-14 | due-trials |
| Reported results | 2014-002447-18 | A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab | 2021-06-18 | due-trials |
| Reported results Terminated | 2014-002587-33 | An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporoti... | 2017-02-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-002807-10 | A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia | 2018-09-30 | bad-data |
| Trial is partly outside EEC | 2014-002950-38 | A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) | bad-data | |
| Reported results | 2014-003262-25 | An open label, single group assignment design study to correlate soluble ST2 with clinical, endoscopic and histological activity in moderate to severe Ulcerative Colitis patients under golimumab | 2017-09-05 | due-trials |
| Reported results | 2014-003304-73 | A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and... | 2016-12-06 | due-trials |
| Reported results | 2014-003347-35 | A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Inf... | 2017-05-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003382-17 | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA? Once-Daily in Treatment-Naïve ... | 2023-09-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-003574-16 | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ... | 2021-07-23 | bad-data |
| Reported results | 2014-003583-20 | A 34-week Follow-up to: A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitaglipt... | 2019-09-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003698-41 | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | 2023-07-19 | bad-data |
| Reported results | 2014-003836-38 | A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Pr... | 2016-02-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-004023-40 | PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI | 2018-09-17 | bad-data |
| Other | 2014-004026-17 | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High Risk Non-muscle Invasive ... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2014-004341-27 | A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History ... | 2018-11-19 | bad-data |
| Trial is outside EEC, and reported results | 2014-004350-34 | A Comparative Bioavailability Study of a Tablet versus an Investigational Oral Suspension of Vorapaxar | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2014-004482-24 | A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) | 2023-09-18 | bad-data |
| Trial is outside EEC, and reported results | 2014-004581-16 | An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years | bad-data | |
| Trial is outside EEC, and reported results | 2014-004582-24 | A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004583-38 | An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects with Persist... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004603-78 | A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention o... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004748-37 | Korean Study of “Real-world” Montelukast Use in Mild Asthmatic Children with Concomitant Allergic Rhinitis | bad-data | |
| Trial is outside EEC, and reported results | 2014-004749-28 | MK-476 Phase III Open Label Exploratory Comparative Study -Acute Exacerbations of Asthma- Protocol number: 334 | bad-data | |
| Trial is outside EEC, and reported results | 2014-004766-15 | MK-518B Food Effect Study | bad-data | |
| Trial is outside EEC, and reported results | 2014-004767-21 | MK-0518B (EU Sourced Lamivudine) Bioequivalence Study | bad-data | |
| Trial is outside EEC, and reported results | 2014-004774-42 | A Phase III, Double-Blind, Randomized, Placebo-Controlled Cross-over Clinical Trial to Study the Efficacy and Safety of MK-0476 in Japanese Pediatric Subjects with Seasonal Allergic Rhinitis. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004775-23 | RADAR: SingulaiR® in Asthma anD Allergic Rhinitis An 8 week multicenter, open-label, observational study to evaluate the effectiveness of adding Montelukast Sodium (SINGULAIR®) 10 mg per day to inhale... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004776-27 | A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK-0476 in Patients with Chronic Asthma | bad-data | |
| Trial is outside EEC, and reported results | 2014-004871-22 | A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old with Perennial Allergic Rhinitis | bad-data | |
| Trial is outside EEC, and reported results | 2014-004875-21 | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05067) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004910-27 | A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Aspergil... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004911-35 | A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children with Documented Candida or Aspergillus Infections | bad-data | |
| Trial is outside EEC, and reported results | 2014-004916-12 | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05106). | bad-data | |
| Trial is outside EEC, and reported results | 2014-004918-28 | PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR) (Protocol No. P05528) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004919-36 | PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004920-23 | PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR) (Protocol No. P05583) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004924-23 | Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Fu... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004925-42 | Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis | bad-data | |
| Other | 2014-004944-37 | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma.: A randomized, double-blind Phase 3 trial of ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2014-004993-40 | A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2014-005021-13 | A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pedi... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005030-54 | A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 M... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005032-34 | A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of Age | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2014-005241-45 | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First... | 2021-06-10 | bad-data |
| Reported results | 2014-005525-13 | A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagliflo... | 2017-10-10 | due-trials |
| Reported results | 2014-005550-18 | A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Tw... | 2023-09-05 | due-trials |
| Trial is outside EEC, and reported results | 2014-005717-23 | A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age | bad-data | |
| Trial is partly outside EEC, and reported results | 2015-000066-62 | A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipe... | 2017-09-18 | bad-data |
| Reported results | 2015-000246-34 | A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazo... | 2019-04-03 | due-trials |
| Reported results | 2015-000294-13 | A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086) Ensayo clínico de fase II de pembrolizumab (MK-3475) en mono... | 2020-01-31 | due-trials |
| Other | 2015-000575-27 | A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (P... | not-yet-due | |
| Exempt, with results | 2015-000681-55 | A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma | 2021-07-14 | not-yet-due |
| Reported results | 2015-000972-88 | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin... | 2022-06-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001020-27 | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) Studio clinico di ... | 2020-11-10 | bad-data |
| Reported results | 2015-001483-19 | A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects with Ch... | 2017-09-25 | due-trials |
| Trial is outside EEC, and reported results | 2015-001656-29 | A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Dise... | bad-data | |
| Reported results | 2015-001658-14 | A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lot Doses and a High Dose of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adult... | 2017-09-29 | due-trials |
| Reported results | 2015-001852-32 | A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Inst... | 2021-02-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-001878-18 | A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (corifollitropin alfa) in Combination with human Chorionic Gonadotropin (hCG) for Initiation... | bad-data | |
| Reported results | 2015-002024-89 | A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) | 2023-07-17 | due-trials |
| Other | 2015-002067-41 | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) | not-yet-due | |
| Reported results | 2015-002134-49 | A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD). | 2018-04-17 | due-trials |
| Trial is outside EEC, and reported results | 2015-002237-22 | A Study to Compare the Pharmacokinetics of a Fixed-Dose Combination of Raltegravir and Lamivudine to Co-administered Raltegravir and Lamivudine | bad-data | |
| Reported results | 2015-002406-37 | A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 2020-10-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002427-26 | A Phase II Study of Pembrolizumab Monotherapy in Third-Line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewe... | 2021-10-29 | bad-data |
| Reported results | 2015-002509-13 | A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183) | 2020-07-16 | due-trials |
| Trial is outside EEC, and reported results | 2015-002778-19 | An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive P... | bad-data | |
| Trial is outside EEC, and reported results | 2015-002779-64 | An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Ther... | bad-data | |
| Trial is outside EEC, and reported results | 2015-002780-42 | A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adoles... | bad-data | |
| Trial is outside EEC, and reported results | 2015-002781-23 | An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who are Concurrently Receiving Standard Antibiotic Therapy for Proven... | bad-data | |
| Reported results | 2015-002782-32 | A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and... | 2022-03-14 | due-trials |
| Reported results | 2015-002901-12 | A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185). | 2020-07-13 | due-trials |
| Trial is outside EEC, and reported results | 2015-002931-16 | A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese men | bad-data | |
| Trial is outside EEC, and reported results | 2015-002932-42 | A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Vir... | bad-data | |
| Trial is partly outside EEC, and reported results | 2015-003006-16 | A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chronic... | 2020-07-23 | bad-data |
| Reported results | 2015-003154-40 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease | 2018-09-30 | due-trials |
| Reported results | 2015-003187-37 | A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV) in... | 2017-01-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003338-29 | A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer | 2021-03-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003616-20 | A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibit... | 2020-10-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003617-18 | Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching from ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Do... | 2024-02-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003644-40 | Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Studio di Fase II con Pembrolizumab (MK - 3475) in soggetti con Carcinoma Prostati... | 2022-03-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003694-15 | A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNO... | 2023-06-22 | bad-data |
| Reported results | 2015-004020-65 | A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continu... | 2021-03-17 | due-trials |
| Trial is outside EEC, and reported results | 2015-004212-37 | A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys | bad-data | |
| Reported results | 2015-004224-59 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Metfor... | 2018-02-01 | due-trials |
| Reported results | 2015-004325-14 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women with Moderate to Severe Primary Dysmenorrhea (with Optional Ext... | 2016-09-07 | due-trials |
| Reported results | 2015-004326-34 | A Phase 3 Randomized, Double-blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 vaginal ring) in Women with Moderate to Severe Primary Dysmenorrhea. | 2016-09-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-004566-28 | A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224) | 2023-09-29 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-004567-36 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) | 2021-09-22 | bad-data |
| Trial is partly outside EEC, and reported results | 2015-004595-29 | A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old | 2018-12-21 | bad-data |
| Reported results | 2015-004990-34 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin Du... | 2018-01-30 | due-trials |
| Other | 2015-005053-12 | A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma | not-yet-due | |
| Reported results | 2015-005054-36 | A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects with Persistent Asthma That is Uncontrolled While Receiving Mont... | 2017-09-06 | due-trials |
| Reported results | 2015-005093-38 | An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to... | 2019-01-21 | due-trials |
| Reported results Terminated | 2015-005284-16 | A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Pharmacodynamics of Etonogestrel (ENG) and 17ß-Estradiol (E2) in Healthy female Postmenarcheal Adolescents and Healthy Female Adults... | 2016-07-14 | due-trials |
| Exempt, with results | 2015-005488-18 | A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors | 2017-04-26 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-005731-41 | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcin... | 2022-09-15 | bad-data |
| Reported results | 2016-000229-38 | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer S... | 2023-09-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000558-37 | A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome | 2022-01-12 | bad-data |
| Other | 2016-000588-17 | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Adva... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000589-47 | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427) | 2022-04-01 | bad-data |
| Reported results Terminated | 2016-000620-26 | A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic Hepa... | 2021-08-24 | due-trials |
| Reported results | 2016-000671-25 | A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subj... | 2019-09-02 | due-trials |
| Reported results | 2016-001117-25 | A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants | 2018-11-30 | due-trials |
| Reported results | 2016-001159-37 | A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects with Chronic Hepatitis C Virus (HCV) Geno... | 2018-10-15 | due-trials |
| Reported results | 2016-001432-35 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negativ... | 2023-10-30 | due-trials |
| Reported results Terminated | 2016-002056-25 | A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabetes M... | 2017-04-18 | due-trials |
| Exempt | 2016-002312-41 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | not-yet-due | |
| Reported results | 2016-003227-37 | A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, ... | 2018-03-05 | due-trials |
| Reported results Terminated | 2016-003257-15 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy Estudio de fase II, randomizado, doble ciego y controlado con placebo... | 2019-09-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-003884-20 | A Phase 3 Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Subjects from Birth to less than 12 Years of Age ... | 2023-09-13 | bad-data |
| Listed as ongoing, but also has a completion date | 2016-003934-25 | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous ce... | 2024-08-21 | bad-data |
| Trial is outside EEC, and reported results | 2016-003981-15 | A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process | bad-data | |
| Trial is partly outside EEC, and reported results | 2016-004153-32 | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjec... | 2021-01-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004309-15 | A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subj... | 2021-09-21 | bad-data |
| Trial is partly outside EEC, and reported results | 2016-004328-43 | A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspect... | 2020-08-11 | bad-data |
| Listed as ongoing, but also has a completion date | 2016-004351-75 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) | 2017-12-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004364-20 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors ... | 2022-09-07 | bad-data |
| Trial is outside EEC, and reported results | 2016-004392-41 | A Study of the Comparative Bioavailability of Two Investigational Pediatric Oral Granule Formulations of Lamivudine and Tenofovir Compared to the Adult Marketed Formulations. Other PIP decision numbe... | bad-data | |
| Other | 2016-004408-76 | A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects... | not-yet-due | |
| Trial is outside EEC, and reported results | 2016-004656-30 | A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation. Additional PIP decision number: ... | bad-data | |
| Trial is outside EEC, and reported results | 2016-004728-48 | A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects | bad-data | |
| Other | 2016-004740-11 | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple ... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2016-004820-41 | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem ... | 2021-01-20 | bad-data |
| Trial is outside EEC, and reported results | 2016-005159-25 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants | bad-data | |
| Trial is outside EEC, and reported results | 2017-000050-18 | A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination with Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and An... | bad-data | |
| Trial is partly outside EEC, and reported results | 2017-000070-11 | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal Antib... | 2022-05-12 | bad-data |
| Trial is outside EEC, and reported results | 2017-000108-42 | A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particle [... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000109-19 | A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000110-35 | Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa. | bad-data | |
| Trial is outside EEC, and reported results | 2017-000111-16 | Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India. | bad-data | |
| Trial is outside EEC, and reported results | 2017-000112-42 | A Phase II Double-Blind Comparative Study of V501 in Females Aged 9 to 17 Years | bad-data | |
| Trial is outside EEC, and reported results | 2017-000186-76 | A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis. | bad-data | |
| Reported results | 2017-000187-15 | A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuron... | 2019-09-04 | due-trials |
| Reported results | 2017-000188-33 | A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vec... | 2019-01-31 | due-trials |
| Trial is outside EEC, and reported results | 2017-000263-32 | A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Rotavirus Reassortant Vaccine in Chinese Healthy Adults, Children and Infants | bad-data | |
| Trial is outside EEC, and reported results | 2017-000264-15 | A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan | bad-data | |
| Trial is outside EEC, and reported results | 2017-000277-37 | Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IP... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-000437-32 | A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose- Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in... | 2022-03-09 | bad-data |
| Reported results Terminated | 2017-000472-28 | A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants with Induced Viral Upper Respiratory Tract Infecti... | 2019-01-04 | due-trials |
| Reported results | 2017-000537-31 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027) | 2020-08-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000594-37 | A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) Estudio de fas... | 2023-09-13 | bad-data |
| Trial is outside EEC, and reported results | 2017-000608-13 | A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria. | bad-data | |
| Trial is outside EEC, and reported results | 2017-000610-26 | A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus. | bad-data | |
| Reported results | 2017-000692-92 | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in ... | 2020-01-28 | due-trials |
| Reported results | 2017-000693-11 | A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in ... | 2023-09-21 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-000953-38 | A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old | 2023-04-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000958-19 | A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-F... | 2023-07-10 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001055-30 | A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus ... | 2022-04-05 | bad-data |
| Trial is partly outside EEC | 2017-001123-53 | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to... | bad-data | |
| Other | 2017-001139-38 | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Advan... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-001205-33 | A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam | bad-data | |
| Trial is outside EEC, and reported results | 2017-001443-13 | A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with an Alternati... | bad-data | |
| Trial is outside EEC, and reported results | 2017-001444-35 | A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly with M-M-R™ II | bad-data | |
| Reported results Terminated | 2017-001463-21 | A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infect... | 2017-10-06 | due-trials |
| Other | 2017-001832-21 | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable... | not-yet-due | |
| Reported results | 2017-001909-32 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight W... | 2020-02-14 | due-trials |
| Trial is outside EEC, and reported results | 2017-001910-27 | A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly w... | bad-data | |
| Listed as ongoing, but also has a completion date | 2017-003134-85 | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) | 2025-06-13 | bad-data |
| Trial is partly outside EEC | 2017-003455-35 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 ... | bad-data | |
| Reported results | 2017-003559-49 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030) | 2020-10-30 | due-trials |
| Reported results | 2017-004024-30 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year... | 2020-07-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-004188-11 | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell L... | 2023-10-02 | bad-data |
| Reported results | 2017-004233-86 | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [... | 2021-08-04 | due-trials |
| Ongoing | 2017-004417-42 | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T... | not-yet-due | |
| Reported results | 2017-004738-27 | A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary A... | 2022-03-09 | due-trials |
| Other | 2017-004869-27 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estro... | not-yet-due | |
| Reported results | 2017-004915-38 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Mont... | 2020-07-02 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-005062-21 | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK 1654 in Pre-Term and Full-Term Infants | bad-data | |
| Reported results | 2018-000066-11 | A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic... | 2021-11-11 | due-trials |
| Ongoing | 2018-000125-30 | An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma | not-yet-due | |
| Other | 2018-000224-34 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 P... | not-yet-due | |
| Other | 2018-000669-35 | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-000714-37 | A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer ... | 2024-03-19 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001038-17 | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in cyt... | 2022-03-16 | bad-data |
| Reported results | 2018-001098-26 | A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | 2020-06-30 | due-trials |
| Trial is outside EEC, and reported results | 2018-001151-12 | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRE... | bad-data | |
| Reported results | 2018-001152-35 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE) | 2020-11-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2018-001326-25 | A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of devel... | 2023-08-25 | bad-data |
| Reported results | 2018-001440-53 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Met... | 2024-06-04 | due-trials |
| Exempt | 2018-001461-16 | A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies | not-yet-due | |
| Ongoing | 2018-001757-27 | A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously ... | not-yet-due | |
| Other | 2018-001967-22 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-ri... | not-yet-due | |
| Other | 2018-001973-25 | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epith... | not-yet-due | |
| Other | 2018-001974-76 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanc... | not-yet-due | |
| Reported results | 2018-002518-10 | A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously E... | 2023-10-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-002520-16 | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Pa... | 2024-11-01 | bad-data |
| Reported results | 2018-002598-22 | A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782) ... | 2021-11-05 | due-trials |
| Reported results | 2018-002601-57 | A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)) | 2024-02-15 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-002983-26 | Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK- 7902) in Combination with Pembrolizumab (MK-3475) Versus... | 2024-09-24 | bad-data |
| Other | 2018-003007-19 | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | not-yet-due | |
| Other | 2018-003009-24 | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001... | not-yet-due | |
| Completed, but no date, and reported results | 2018-003202-82 | Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Pipera... | bad-data | |
| Reported results | 2018-003308-38 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU - LINK) | 2021-03-26 | due-trials |
| Other | 2018-003347-28 | A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated with Experimental Respiratory Syncytial Virus. | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2018-003706-88 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch -up Vaccination Regimens of V114 in Healthy Infant... | 2020-12-09 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-003747-37 | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) | 2024-10-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003752-21 | A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Tr... | 2024-05-20 | bad-data |
| Trial is partly outside EEC, and reported results | 2018-003787-31 | A Phase 3, Multicenter, Randomized, Double-blind, Active -comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1) | 2021-08-05 | bad-data |
| Reported results | 2018-003788-70 | A Phase 3, Multicenter, Randomized, Double-blind, Active-comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU... | 2021-11-02 | due-trials |
| Other | 2018-003791-12 | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated... | not-yet-due | |
| Reported results | 2018-003794-98 | A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whos... | 2024-04-24 | due-trials |
| Other | 2018-003808-39 | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Par... | not-yet-due | |
| Other | 2018-003809-26 | A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905) | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-003824-35 | A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-l... | 2024-08-30 | bad-data |
| Trial is outside EEC, and reported results | 2018-004109-21 | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED) | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004116-22 | A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Cas... | 2023-07-18 | bad-data |
| Other | 2018-004117-40 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KE... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004118-16 | A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) W... | 2024-01-27 | bad-data |
| Reported results | 2018-004266-33 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years... | 2020-07-03 | due-trials |
| Reported results | 2018-004316-22 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-A... | 2020-07-02 | due-trials |
| Other | 2018-004320-11 | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medic... | not-yet-due | |
| Trial is partly outside EEC | 2018-004704-19 | A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosoco... | bad-data | |
| Other | 2018-004720-11 | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treat... | not-yet-due | |
| Other | 2018-004721-88 | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Met... | not-yet-due | |
| Ongoing | 2018-004800-20 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Rad... | not-yet-due | |
| Reported results | 2018-004843-22 | A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Partici... | 2020-06-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-004844-43 | A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) ... | 2021-02-11 | bad-data |
| Reported results | 2019-000069-19 | Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Par... | 2022-01-27 | due-trials |
| Reported results Terminated | 2019-000305-79 | An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients with Char... | 2019-09-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2019-000338-20 | A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 1... | 2024-07-12 | bad-data |
| Trial is outside EEC, and reported results | 2019-000341-12 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight We... | bad-data | |
| Other | 2019-000569-19 | Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemother... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-000586-20 | A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretrovi... | 2024-08-26 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-000587-23 | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegra... | 2025-02-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000588-26 | A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/... | 2023-11-01 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-000590-23 | A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment... | 2025-01-29 | bad-data |
| Reported results | 2019-000698-22 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or M... | 2023-10-04 | due-trials |
| Other | 2019-000944-82 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable B... | not-yet-due | |
| Other | 2019-001745-40 | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-... | not-yet-due | |
| Other | 2019-001892-35 | An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in ... | not-yet-due | |
| Other | 2019-002006-51 | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYN... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-002034-36 | A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastat... | 2023-07-17 | bad-data |
| Trial is partly outside EEC, and reported results | 2019-002267-10 | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis | 2023-12-18 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002308-42 | A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough | 2021-11-03 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002321-29 | A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence | 2022-09-02 | bad-data |
| Ongoing | 2019-002345-37 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with ... | not-yet-due | |
| Reported results | 2019-003048-63 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis. | 2023-04-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-003060-42 | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Mono... | 2022-09-30 | bad-data |
| Other | 2019-003152-37 | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11) | not-yet-due | |
| Other | 2019-003236-23 | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Viruslike P... | not-yet-due | |
| Other | 2019-003237-41 | A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Dur... | not-yet-due | |
| Other | 2019-003444-72 | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2019-003597-10 | A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years of ... | 2023-01-25 | bad-data |
| Exempt | 2019-003609-84 | A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03A | not-yet-due | |
| Exempt | 2019-003610-13 | A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B | not-yet-due | |
| Other | 2019-003616-31 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-733... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-003633-41 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Can... | 2024-03-19 | bad-data |
| Trial is outside EEC, and reported results | 2019-003644-68 | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants | bad-data | |
| Exempt, with results | 2019-003703-35 | A Phase 1/2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | 2024-04-08 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2019-003717-34 | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and le... | 2025-03-31 | bad-data |
| Trial is partly outside EEC | 2019-003842-34 | A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulati... | bad-data | |
| Trial is outside EEC, and reported results | 2019-003903-36 | An Open-Label, Multicenter, Single-arm Study to Evaluate the Immunogenicity of VARIVAX™ in Healthy Russian Individuals 12 Months of Age and Older | bad-data | |
| Trial is outside EEC | 2019-003955-13 | A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine in Participants With HIV-1 Aged 4 Weeks to <12 Years of Age and Weighing <35 kg | bad-data | |
| Exempt | 2019-003956-35 | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A | not-yet-due | |
| Exempt | 2019-003977-24 | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B | not-yet-due | |
| Exempt | 2019-003978-22 | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C | not-yet-due | |
| Ongoing | 2019-004023-20 | A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Parti... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2019-004441-33 | An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies | bad-data | |
| Completed, report not yet due | 2020-000094-24 | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia | 2024-09-24 | not-yet-due |
| Reported results | 2020-000126-26 | A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dos... | 2021-03-08 | due-trials |
| Trial is outside EEC | 2020-001047-67 | A Phase 3, randomized, placebo-controlled clinical study to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in Japanese males, 16 to 26 years of age. | bad-data | |
| Other | 2020-001108-40 | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-001170-29 | A Phase 3, Open-label Clinical Study to Evaluate the Immunogenicity and Safety of 9vHPV Vaccine, in Japanese Boys and Girls, 9 to 15 Years of Age. | bad-data | |
| Ongoing | 2020-001191-14 | A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-001576-15 | A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years with Complicated Skin ... | bad-data | |
| Other | 2020-001626-56 | KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small C... | not-yet-due | |
| Other | 2020-001627-14 | KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell... | not-yet-due | |
| Other | 2020-001629-29 | KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously... | not-yet-due | |
| Other | 2020-001907-18 | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | not-yet-due | |
| Exempt, with results | 2020-001908-42 | A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors | 2023-07-26 | not-yet-due |
| Other | 2020-001911-26 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Part... | not-yet-due | |
| Other | 2020-001990-53 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Interv... | not-yet-due | |
| Other | 2020-002075-35 | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma ... | not-yet-due | |
| Other | 2020-002216-52 | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Le... | not-yet-due | |
| Other | 2020-002324-36 | A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies | not-yet-due | |
| Other | 2020-002397-27 | A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patien... | not-yet-due | |
| Trial is partly outside EEC | 2020-002405-26 | A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full- Term Infants Studio di fase 2b/3 in doppio cieco, random... | bad-data | |
| Other | 2020-002729-27 | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, ... | not-yet-due | |
| Other | 2020-003071-18 | A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on B... | not-yet-due | |
| Other | 2020-003106-31 | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with M... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-003181-39 | A Phase 3, Single-Arm, Open-label Clinical Study to Evaluate the Safety and Immunogenicity of 4 doses of V114 Administered to Healthy Infants in South Korea. | bad-data | |
| Trial is partly outside EEC, and reported results | 2020-003309-79 | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Wo... | 2023-08-04 | bad-data |
| Trial is outside EEC, and reported results | 2020-003329-49 | A Phase 3 Randomized, Open-Label, Clinical Trial to Study the Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of V260 and Inactivated Poliomyelitis Vaccine (IPV) in Chinese... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2020-003367-26 | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | 2021-08-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-003368-24 | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19 | 2022-05-05 | bad-data |
| Other | 2020-003424-17 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometr... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-003731-22 | A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets | bad-data | |
| Other | 2020-003736-24 | A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boy... | not-yet-due | |
| Exempt | 2020-003742-36 | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D | not-yet-due | |
| Other | 2020-004034-38 | A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-sma... | not-yet-due | |
| Other | 2020-004049-35 | A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 ... | not-yet-due | |
| Ongoing | 2020-004087-26 | A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61) | not-yet-due | |
| Reported results | 2020-004142-11 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy fo... | 2022-12-06 | due-trials |
| Completed, report not yet due | 2020-004289-20 | A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Bec... | 2024-09-27 | not-yet-due |
| Other | 2020-004490-52 | A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participan... | not-yet-due | |
| Completed, reported early | 2020-004501-30 | A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [live, attenuated]) in ... | 2024-08-09 | not-yet-due |
| Exempt | 2020-004544-28 | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Car... | not-yet-due | |
| Other | 2020-005007-40 | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | not-yet-due | |
| Other | 2020-005027-37 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (K... | not-yet-due | |
| Other | 2020-005028-13 | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrin... | not-yet-due | |
| Other | 2020-005061-13 | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH | not-yet-due | |
| Other | 2020-005114-18 | A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-H) ... | not-yet-due | |
| Reported results | 2020-005136-30 | A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease | 2022-10-19 | due-trials |
| Other | 2020-005407-38 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive,... | not-yet-due | |
| Ongoing | 2020-005609-20 | A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-ce... | not-yet-due | |
| Exempt | 2020-005628-12 | A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell... | not-yet-due | |
| Other | 2020-005649-17 | A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants... | not-yet-due | |
| Other | 2020-005941-18 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection ... | not-yet-due | |
| Trial is partly outside EEC | 2020-005996-11 | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Sev... | bad-data | |
| Ongoing, reported early | 2021-000091-11 | A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active U... | not-yet-due | |
| Ongoing, reported early | 2021-000092-37 | A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease | not-yet-due | |
| Ongoing, reported early | 2021-000199-12 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-r... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-000904-39 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With... | 2022-11-16 | bad-data |
| Exempt, with results Terminated | 2021-001004-15 | A Phase 1b/2 Open-Label, Multiple-Ascending Dose Study Followed by a Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy ... | 2023-10-18 | not-yet-due |
| Other | 2021-001009-56 | A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selec... | not-yet-due | |
| Other | 2021-001244-95 | Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11) | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-001289-39 | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for... | bad-data | |
| Listed as ongoing, but also has a completion date | 2021-001309-60 | A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer Klinické hod... | 2025-02-21 | bad-data |
| Other | 2021-001369-19 | A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies Spe... | not-yet-due | |
| Other | 2021-001498-21 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) Worl... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-001700-15 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK- 7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematologic... | 2024-12-10 | bad-data |
| Other | 2021-003020-32 | Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hype... | not-yet-due | |
| Other | 2021-003185-12 | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re... | not-yet-due | |
| Other | 2021-003313-18 | A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B... | not-yet-due | |
| Other | 2021-003397-32 | A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | not-yet-due | |
| Other | 2021-003436-92 | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme... | not-yet-due | |
| Trial is outside EEC | 2021-003591-13 | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomit... | bad-data | |
| Reported results | 2021-004053-23 | A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Va... | 2023-01-17 | due-trials |
| Other | 2021-004450-36 | A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies | not-yet-due | |
| Other | 2021-004564-94 | A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastati... | not-yet-due | |
| Other | 2021-005034-42 | A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma... | not-yet-due | |
| Other | 2021-005135-23 | Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy follow... | not-yet-due | |
| Ongoing, reported early | 2021-005206-10 | A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) | not-yet-due | |
| Reported results | 2021-005221-24 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia | 2022-11-28 | due-trials |
| Exempt | 2021-005405-26 | A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U0... | not-yet-due | |
| Exempt | 2021-005443-76 | A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment... | not-yet-due | |
| Other | 2021-005458-27 | A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer | not-yet-due | |
| Other | 2021-005861-41 | A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL Estudio de f... | not-yet-due | |
| Other | 2021-006336-94 | A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia S... | not-yet-due | |
| Reported results | 2021-006679-41 | A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older | 2023-06-22 | due-trials |
| Reported results | 2021-006710-36 | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV | 2024-05-30 | due-trials |
| Exempt, with results | 2021-006712-93 | A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors | not-yet-due | |
| Reported results | 2022-000258-27 | A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults | 2023-06-21 | due-trials |
| Reported results | 2022-000265-41 | A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age | 2023-07-03 | due-trials |
| Other | 2022-000371-39 | A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C... | not-yet-due | |
| Other | 2022-000478-25 | A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard of... | not-yet-due | |
| Other | 2022-000836-49 | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-lin... | not-yet-due | |
| Exempt | 2022-001371-14 | A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as Fir... | not-yet-due | |
| Other | 2022-001785-35 | A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age o... | not-yet-due | |
| Trial is outside EEC | 2022-003483-25 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age | bad-data | |
| Trial is outside EEC, and reported results | 2023-001144-29 | A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-1... | bad-data | |
| Trial is outside EEC | 2024-000582-24 | A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese females 9 to 45 Years of Age | bad-data |